LOUISVILLE, Colo., May 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that new data will be presented at the 2025 American Society ...
A blood test that offers prognostic information on patients with non–small cell lung cancer (NSCLC) who do not have an EGFR mutation can reduce the costs of end-of-life treatment while improving ...
Biodesix Inc. has announced that its VeriStrat® blood-based prognostic and predictive proteomics test has been approved for inclusion in the National Comprehensive Cancer Network Clinical Practice ...
BOULDER, Colo.--(BUSINESS WIRE)--Study results presented today demonstrate the feasibility of running the VeriStrat ® test on Bioyong’s Clin-TOF platform, and provide a basis for validating and ...
The study retrospectively evaluated VeriStrat classification prior to the start of treatment with gefitinib, during the course of treatment, and at progression or withdrawal from treatment. VeriStrat ...
NCCN recommended the diagnostic proteomic test to identify patients who can receive erlotinib as second-line therapy. Biodesix Inc., a molecular diagnostics company dedicated to advancing precision ...
BOULDER, Colo. and CHICAGO, Sept. 6, 2012 /PRNewswire/ -- Results from the VeriStrat analysis of serum samples taken from a Phase II study evaluating erlotinib plus high-dose celecoxib (E+C) or ...
Despite the potential utility of this test, its use has remained rather limited. In my experience with it, patients with a VeriStrat Good profile tended to have a prolonged survival after receiving an ...
BROOMFIELD, Colo., Nov. 22, 2011 /PRNewswire/ -- Biodesix today announced that results from a prospectively designed, retrospective analysis of serum samples from the phase III study, EGF30008, will ...
BROOMFIELD, Colo.--(BUSINESS WIRE)-- Biodesix Inc, a fully integrated molecular diagnostic company dedicated to personalizing medicine, announced today the publication of “Changes in plasma ...
BROOMFIELD, Colo., Nov. 22, 2011 /PRNewswire/ -- Biodesix today announced that results from a prospectively designed, retrospective analysis of serum samples from the phase III study, EGF30008, will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results